Jiangsu Lianhuan Pharmaceutical's (SHA:600513) unit, Xinxiang Changle Pharmaceutical, received approval for a drug supplement application for estazolam tablets after it passed the regulatory consistency evaluation, according to a Shanghai bourse filing on Friday.
The drug, which is used to treat anxiety and insomnia, was tested for its consistency in quality and efficacy.
The pharmaceutical company invested 4.8 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments